FDA OKs Gilead’s paediatric hep C drug
Epclusa is the first pan-genotypic, protease inhibitor-free regimen approved in the United States for adults and children.
Read More
Tag: America
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
